Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, October 5, 2023
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
[ Thu, Oct 05th 2023
] - WOPRAI
Wed, October 4, 2023
[ Wed, Oct 04th 2023
] - WOPRAI
[ Wed, Oct 04th 2023
] - WOPRAI
[ Wed, Oct 04th 2023
] - WOPRAI
[ Wed, Oct 04th 2023
] - WOPRAI
[ Wed, Oct 04th 2023
] - WOPRAI
[ Wed, Oct 04th 2023
] - WOPRAI
[ Wed, Oct 04th 2023
] - WOPRAI
[ Wed, Oct 04th 2023
] - WOPRAI
[ Wed, Oct 04th 2023
] - WOPRAI
[ Wed, Oct 04th 2023
] - WOPRAI
[ Wed, Oct 04th 2023
] - WOPRAI
[ Wed, Oct 04th 2023
] - WOPRAI
[ Wed, Oct 04th 2023
] - WOPRAI
[ Wed, Oct 04th 2023
] - WOPRAI
[ Wed, Oct 04th 2023
] - WOPRAI
[ Wed, Oct 04th 2023
] - WOPRAI
[ Wed, Oct 04th 2023
] - WOPRAI
[ Wed, Oct 04th 2023
] - WOPRAI
[ Wed, Oct 04th 2023
] - WOPRAI
[ Wed, Oct 04th 2023
] - WOPRAI
Raghuram Selvaraju Reiterated (ACRS) at Strong Buy and Held Target at $43 on, Oct 4th, 2023
Raghuram Selvaraju of HC Wainwright & Co., Reiterated "Aclaris Therapeutics, Inc." (ACRS) at Strong Buy and Held Target at $43 on, Oct 4th, 2023.
Raghuram has made no other calls on ACRS in the last 4 months.
There are 3 other peers that have a rating on ACRS. Out of the 3 peers that are also analyzing ACRS, 0 agree with Raghuram's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Raghuram
- Gavin Clark-Gartner of "Evercore ISI Group" Initiated at Buy and Held Target at $22 on, Tuesday, October 3rd, 2023
- Louise Chen of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $38 on, Tuesday, September 19th, 2023
- Alex Thompson of "Stifel" Maintained at Strong Buy with Increased Target to $20 on, Thursday, September 14th, 2023
